The ADJUVANT/CTONG1104 study (NCT01405079) revealed that gefitinib was better than chemotherapy in increasing the DFS (28.7 vs 18.0 months, HR = 0.60, 95% CI: 0.42–0.87, p = 0.0054) in completely resected stage II-IIIA (N1-N2) EGFR mutation-positive NSCLC (11). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.